Citadel Advisors’s Regentis Biomaterials RGNT Stock Holding History

Citadel Advisors’s Portfolio RGNT Stock Details RGNT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-10,412	Closed	-$70.2K	–	14844
2025 Q4	$70.2K	Buy	+10,412	New	+$71.4K	﹤0.01%	11864

Other funds holding RGNT

ACM

AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Citadel Advisors's RGNT Position: Q1 2026 in Review

Citadel Advisors sold out of Regentis Biomaterials (RGNT) in Q1 2026, closing a stake of 10,412 shares — an estimated $70.2K sold.

Citadel Advisors first reported a position in RGNT in Q4 2025 and held it in 1 quarter. The position peaked at $70.2K in Q4 2025. 3 funds tracked by Wall St. Rank hold RGNT as of Q1 2026.

Citadel Advisors reported no remaining Regentis Biomaterials position as of Q1 2026 after selling out during the quarter.
Citadel Advisors sold 10,412 Regentis Biomaterials shares in Q1 2026, an estimated $70.2K.
Citadel Advisors first reported a position in Regentis Biomaterials in Q4 2025 and held it in 1 quarter.
Citadel Advisors's Regentis Biomaterials position peaked at $70.2K in Q4 2025.
3 funds tracked by Wall St. Rank held Regentis Biomaterials as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.